Ask AI
ProCE Banner Activity

Personalizing Bispecific Antibody Therapy for Your Patients With Multiple Myeloma: Clinical Fundamentals, Current Evidence, and Expert Strategies for Community HCPs

Slideset

These slides illustrate the rapidly evolving role of bispecific antibodies (BsAbs) in multiple myeloma, with a focus on BCMA- and GPRC5D-directed therapies, their mechanisms of action, pivotal and emerging clinical trial data, and characteristic safety considerations such as cytokine release syndrome, neurotoxicity, infection risk, and target-specific adverse events. The slide deck also illustrates BsAb combination regimens, sequences after prior BCMA-directed therapy, potential mechanisms of treatment failure, and the relative clinical and logistical considerations of BsAbs vs CAR T-cell therapy. The slide set in this module helps visually conceptualize where BsAbs may fit within individualized treatment strategies for patients with relapsed/refractory multiple myeloma.

Released: August 18, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for hematologists, oncologists, emergency medicine physicians, neurologists, infectious disease specialists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with multiple myeloma who are eligible for or receiving bispecific antibody therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess each patient’s eligibility and potential barriers to receiving bispecific antibodies that are approved or under investigation in MM

  • Personalize treatment using approved or investigational bispecific antibodies for each eligible patient with MM, considering available data, expert recommendations, and patient preferences

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.